Introduction: Cardiopulmonary exercise testing (CPET) plays an important role in properly phenotyping signs and symptoms of heart failure with preserved ejection fraction (HFpEF). The prognostic value of CPET is strengthened when accompanied by cardiac hemodynamic measurements. Although recognized as the ''gold'' standard, cardiac catheterization is impractical for routine CPET. Thus, advancing the scientific/methodologic understanding of noninvasive techniques for exercise cardiac hemodynamic assessment is clinically impactful in HFpEF. This study tested the concurrent validity of noninvasive acetylene gas (C 2 H 2 ) uptake, echocardiography (ECHO), and oxygen pulse (O 2pulse ) for measuring/predicting exercise stroke volume (SV) in HFpEF. Methods: Eighteen white HFpEF and 18 age-/sex-matched healthy controls participated in upright CPET (ages, 69 T 9 yr vs 63 T 9 yr). At rest, 20 W, and peak exercise, SV was measured at steady-state via C 2 H 2 rebreathe (SV ACET ) and ECHO (SV ECHO 
Constituting a clinically impactful step towards construct validation testing, these data suggest SV ACET , SV ECHO , and O 2pulse demonstrate moderate-to-strong concurrent validity for measuring/predicting exercise SV in HFpEF. Key Words: CARDIAC OUTPUT, ECHOCARDIOGRAPHY, CPET, INERT GAS BREATHING, HEART FAILURE WITH PRESERVED EJECTION FRACTION C ardiopulmonary exercise testing (CPET) plays an important role in properly phenotyping signs and symptoms of patients with heart failure with preserved ejection fraction (HFpEF) (6, 17, 27, 29, 34) . Whether exercise intolerance linked to HFpEF manifests directly from pathophysiology of central (e.g., impaired inotropy and lusitropy ( [1, 5, 6, 24, 29] )) and/or peripheral (e.g., skeletal muscle ( [21] )) factors, there are immediately recognizable clinical implications associated with a reduced cardiac hemodynamic response during CPET in HFpEF.
The direct Fick approach requiring steady-state measures of pulmonary oxygen uptake (V O 2 ) and invasive arterial and mixed venous O 2 samples for quantifying arteriovenous oxygen content difference (A-V O 2 ) is the ''gold'' standard for measuring cardiac output (Q ) and stroke volume (SV) (20) . However, clinically impactful factors including increased patient risk (3) and required resources (e.g., specialists and costs) make implementing the direct Fick method during routine CPET impractical. Therefore, because of the prognostic power associated with evaluating exercise cardiac hemodynamics in HFpEF (1, 5, 6, 17, 24, 29) , there is a high-priority need to advance the understanding of unique scientific and methodologic factors influential to assessing noninvasive exercise cardiac hemodynamics in generalizable laboratory settings in HFpEF.
Noninvasive imaging methods for assessing cardiac hemodynamics involving echocardiography (ECHO) have been validated in controlled environments (19, 32) . However, primary limitations of ECHO, which are pronounced during exercise, are that image acquisition and postprocessing are highly sensitive to patient factors (e.g., obesity, body position, and so on) and subjective interpretations of personnel (23, 25) . By contrast, perfusion sensitive inert gas pulmonary uptake techniques involving for example, acetylene (C 2 H 2 ) (Bunsen solubility coefficient in blood is 0.740, approximately two times that of carbon dioxide [CO 2 [8, 15, 16, 36] )) have demonstrated utility for objectively measuring Q and SV at rest and/or exercise in adults across the health spectrum (2, 13, 16, 33) . While observations from validation studies support the usefulness of inert gas uptake methods for measuring Q and SV in patients demonstrating overt cardiac and/or pulmonary limitations (2, 13, 16, 33) , we recognize that marked perturbations in specific factors (e.g., low lung diffusing capacity ( [17, 30] )) affecting ventilation-perfusion (V A /Q ) matching could render results from these approaches open to question. Likewise, any factor disturbing V A /Q matching influential to inert gas uptake methods would affect interpretability of oxygen pulse (O 2pulse ), which has been validated for predicting exercise SV given invariability in A-V O 2 and HR (37, 40) .
Although separate lines of study have tested the utility of C 2 H 2 uptake, ECHO, and O 2pulse for measuring or predicting rest and/or exercise SV in a spectrum of adults (2, 16, 19, 20, 33, 37) , those data cannot be immediately extrapolated to the unique population of HFpEF. There are immediate clinical implications linked to exercise cardiac hemodynamic testing in HFpEF (1, 5, 6, 17, 24, 29) . Therefore, this study aimed to test concurrent validity across C 2 H 2 uptake, ECHO, and O 2pulse for noninvasively measuring or predicting exercise SV in patients with HFpEF.
METHODS
Participants. Eighteen white HFpEF patients and 18 white healthy control participants matched for age and sex participated in this study (demographics, Table 1 ). Inclusion criteria for HFpEF at initial study screening were (27) (28) (29) 34) : left ventricular ejection fraction (LVEF) Q50% (within the previous 6 months), stable pharmacologic therapy Q1 month, evidence of elevated left heart filling pressures (i.e., mitral E/e ¶ 915, or mitral E/e ¶ 98 plus either enlarged left atrial volume (934 mLIm 2 ), chronic loop diuretic use for control of symptoms, or elevated natriuretic peptides (B-type natriuretic peptide [BNP] or NT-proBNP levels between 35 and 250 pgImL j1 or 125 and 300 pgImL j1 , respectively), and absence of diagnosed lung disease (e.g., chronic obstructive pulmonary disease, pulmonary hypertension, and so on.) independent or secondary to HFpEF. Exclusion criteria for HFpEF were (within the previous 6 months) evidence of significant coronary artery disease (requiring for example, an angioplasty, coronary artery bypass grafting, and so on), valvular heart disease (any stenosis, 9mild regurgitation), hypertrophic or infiltrative cardiomyopathy, constrictive pericarditis, exercise-induced PH due to vascular disease (mean exercise pulmonary artery pressure 930 mm Hg with pulmonary capillary wedge pressure G15 mm Hg), or radiographic evidence of pulmonary congestion were excluded. The Mayo Clinic Heart Failure Service and the Cardiovascular Health Clinic were used to recruit HFpEF. Controls were recruited through advertisement in the surrounding community. Controls had normal cardiac function without evidence of exercise-induced ischemia and were without history of hypertension, lung disease, or coronary artery disease. The present analysis represents a substudy aim as well as subset of data from original work (7) . However, the parts of these data that have been published previously do not relate to the primary aims of this article. All aspects of this study were reviewed and approved by the Mayo Clinic Institutional Review Board, and all participants provided written informed consent prior to study participation.
Protocol. Upon arrival to the environmentally controlled physiology laboratory and after assessing body anthropometrics (e.g., height, weight, and so on), participants performed resting flow-volume loop spirometry (CPFS system spirometer; Medical Graphics, St. Paul, MN) while sitting upright according to American Thoracic Society (ATS) criteria for measures of forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV 1 ) (11), whereas percent predicted FVC and FEV 1 were computed according to Crapo et al. (11) . Participants were then fitted with a 12-lead electrocardiogram (Marquette Electronics, Milwaukee, WI) to monitor HR and rhythm and assumed an upright seated position on a cycle ergometer (Corival Lode B.V., Netherlands) where C 2 H 2 uptake (36) . Briefly, participants breathed into a non-rebreathing threeway pneumatic switching valve (Hans Rudolph, Kansas City, MO) connected to a pneumotachometer (Hans Rudolph) and gas mass spectrometer (Perkin Elmer MGA-1100, Wesley, MA), which were integrated with custom analysis software for the determination of Q ACET (36) . The inspiratory port of the switching valve allowed for rapid switching for breathing room air or from a 5-L anesthesia rebreathe bag (Hans Rudolph) containing 1 to 3 L of test gas [0.65% C 2 H 2 , 9% helium [He] , balance N 2 , and 35% O 2 ], depending on initial V T of the participant and the exercise intensity as previously described (36) .
Gas concentrations were continuously measured beginning with the first end expiration of the rebreathe period using gas mass spectrometry (36) . Acetylene is not diffusion limited and does not readily bind to hemoglobin while demonstrating high solubility in blood (8, 15, 16) . Therefore, uptake of C 2 H 2 in pulmonary blood demonstrates linearity with the rate of pulmonary capillary hemodynamics. As such, the rate of decrease in the end-tidal concentration of C 2 H 2 with each breath to determine SV ACET is calculated from the slope of the exponential end-tidal decrease in C 2 H 2 concentration with respect to the end-tidal concentration of the blood-insoluble gas He (36) .
According to the direct Fick equation and modifications of Grollman (15) , Q ACET , as well as SV ACET using HR can be calculated using C 2 H 2 as follows:
where V O 2 is pulmonary oxygen uptake acquired using gas mass spectrometry, (C 2 H 2 ) diff is the amount of C 2 H 2 absorbed per liter of blood during the time of sampling, (O 2 ) diff is the amount of O 2 absorbed during the sampling period, x C 2 H 2 is the average concentration of C 2 H 2 during the sampling period, P b is barometric pressure, 47 is the assumed vapor pressure of water in lungs (mm Hg), and 0.00974 is a numerical constant derived by combining the constants 760, 100, and 740, which represents the solubility coefficient for C 2 H 2 in blood at body temperature (15) .
Echocardiography. While image acquisition for SV via ECHO (SV ECHO ) took longer than C 2 H 2 uptake periods, all measurements of SV ECHO were acquired within the final 1.5 min of each CPET stage by the same trained research cardiac sonographer using standard two-dimensional and pulsed wave tissue Doppler imaging (PW-TDI) using the Vivid 7 ECHO system (GE Medical Systems, Milwaukee, WI). Images were stored offline for analyses using EchoPac (v.5.0, GE Medical Systems). Echocardiographic image analyses were blinded to participant condition (HFpEF vs control) and activity state (rest vs 20 W vs peak exercise). The same sonographer as well as ECHO reader were used for all studies (both individuals, 910 yr working with stress ECHO data acquisition and interpretation).
Measurements of SV ECHO were obtained according to standards of the American Society of Echocardiography using the left ventricular outflow tract (LVOT) method, which included the apical five-chamber and parasternal long-axis views (23) . Briefly, in the parasternal long-axis view, 5 to 10 consecutive cardiac cycles of the LVOT at the aortic annulus were captured using gray scale two-dimensional imaging. Crosssectional area (CSA) of the LVOT-proximal to the aortic valve points of insertion of the LVOT was measured at the time point of maximal separation of aortic valve leaflets nearend systole. The CSA value used for analysis was the average of five cardiac cycles and calculated as: CSA = Pr 2 , where r is the radius of the LVOT.
In the apical five-chamber view using PW-TDI imaging, with the pulsed-wave beam focused at the depth of the LVOT-proximal to the aortic valve points of insertion of the velocity-time integral of the flow entering the LVOT during systole was measured using GE EchoPac . The average velocity-time integral of five cardiac cycles was used for the calculation of SV as: Statistical analyses. Parametric data are presented as mean T SD. D_Agostino & Pearson omnibus testing confirmed normality of data, whereas Levene_s testing confirmed homoscedasticity of data. In a progressive manner to test the validity (18) of techniques across SV ECHO , SV ACET , and O 2pulse , 1) univariate linear models via ordinary least squares regression (coefficient of determination, R 2 ) were performed separately for each group for the periods of rest, 20 W, and peak exercise; 2) the goodness of fit equation (i.e., y = mx + b) and R means of complementing the interpretive value of SEE tests (18) , residuals and predicted values of SV derived from combined linear regression and SEE modeling were plotted for each time point of interest across techniques. Betweengroup differences in R 2 were compared using Fisher's Z transformation test. Power of regression models and standard interpretation of R 2 were based on thresholds of Cohen (10): modest = 0.02, moderate = 0.15, and strong Q 0.25; power Q0.80. Analysis of variance models with repeated measures were used to test between and within group differences for dependent variables of interest during CPET (group-time interaction terms set in all models). In the event of significant interaction terms, Tukey post hoc testing was performed to identify between-within pairwise differences. Two-tailed significance was determined using an alpha level set at 0.05. All computations were performed using SAS statistical software (v.9.4.) (SAS Institute, Cary, NC).
RESULTS
Although there were no differences between controls and HFpEF for basic demographics (Table 1) , HFpEF demonstrated a lower percent predicted peak V O 2 compared to controls, which was consistent with 89% of HFpEF classified as Weber-Janicki class C or D. Although no HFpEF demonstrated a formal diagnosis of a pulmonary related comorbidity independent or secondary to HFpEF, reduced resting airway function was present in HFpEF (Table 1) . However, decreased resting airway function in HFpEF suggested, for example, by low absolute FVC or FEV 1 , did not explain the variance associated with SV ECHO , SV ACET , or O 2pulse at either 20 W (FVC, R 2 = 0.03, 0.00, or 0.00, respectively, all P 9 0.50; and FEV 1 , R 2 = 0.00, 0.02, or 0.01, respectively, all P 9 0.60) or peak exercise (FVC, R 2 = 0.01, 0.02, or 0.05, respectively, all P 9 0.30; and FEV 1 , R 2 = 0.00, 0.02, or 0.05, respectively, all P 9 0.30) in HFpEF.
In addition to the proportion of women and presence of hypertension in HFpEF demonstrating consistency with published literature, all criteria used to classify patients as HFpEF for this study including LVEF (range, 50%-62%), blood biochemistry, resting ECHO (e.g., increased left atrial volume index, increased mitral E/e ¶ ratio, and so on), and pharmacologic therapy (960% of HFpEF were on A blockers or diuretics, whereas approximately one third to two fifths were on ACE inhibitors, ARBs, aspirin, or nitrates) were generally met in accordance with consensus statements and recommendations for the diagnosis of HFpEF (27, 29, 34, 39) . All participants completed testing without adverse events. Routine pharmacologic therapy for HFpEF patients was maintained during testing.
Rest and CPET responses. Although group-time interaction terms were significant for all dependent variables of interest presented in Table 2 (all P G 0.05), following post hoc Tukey testing, there were no between-group differences at rest for metrics descriptive of symptoms, ventilation, gas exchange, or cardiovascular function. Similarities at rest between groups persisted at matched 20 W of exercise except for HFpEF demonstrating a higher RER compared with controls. At peak exercise, however, W were lower in HFpEF compared to controls despite similar RPE and RER (Table 2) . Differences in peak W were mirrored by blunted increases in V O 2 (both absolute and weight indexed), V CO 2 , V E , and V T at peak Raw data are presented as mean T SD. Controls (n = 18); HFpEF (n = 18). P values and symbols reflect Tukey post hoc correction. *P G 0.05, all differed within group. **P G 0.05, within group, peak versus 20 W and rest. ***P G 0.05, within group, peak versus 20 W. ****P G 0.05, within group, peak versus rest. SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; SpO 2 , oxygen saturation.
exercise in HFpEF compared to controls; whereas RR and P ET CO 2 did not differ (Table 2) .
Resembling the lack of between-group ventilation and gas exchange differences at rest and at 20 W, there were no betweengroup differences for any cardiovascular based metric in Table 2 . However, peak exercise HR, systolic blood pressure, mean arterial pressure, and O 2pulse were lower in HFpEF compared with controls, whereas diastolic blood pressure, SV ECHO , SV ACET , A-V O 2 (both ECHO and C 2 H 2 ), and SaO 2 did not differ between groups. R 2 and SEE between techniques for measurement or estimation of SV. Illustrated in Figure 1 (A to C) are modest strength univariate regressions at rest for controls when setting SV ECHO to explain the variance in SV ACET (R 2 did not change when flipping SV ACET to predict SV ECHO ACET . By comparison, the same relationship testing performed in Figure  1 , panels D to F, in HFpEF were strong at rest while differing in R 2 between groups for panels C versus F (P = 0.02), but not for A versus D (P = 0.33) or B versus E (P = 0.11). Likewise, the smaller standardized SEE output in Table 3 along with the more favorable data spread for each residual versus predicted SV plot within HFpEF in Figure 1 (Fig. 2 , A to C) markedly weaker compared with the same relationships tested in HFpEF FIGURE 1-Ordinary least squares univariate linear regressions between noninvasive techniques for measuring or predicting SV at rest in healthy controls (CTL) or patients with heart failure with preserved ejection fraction (HFpEF). Solid line represents the goodness of fit line with 95% confidence limits as dotted lines. Goodness of model fit expressed as coefficient of determination (R 2 ) from Cohen (10); modest, 0.02; moderate, 0.15; and strong, Q 0.25. For panels A to F, the variable set on the abscissa was considered the practical method, whereas the variable set on the ordinate was considered the quasicriterion method. Panels G to I align vertically with panels A to C or D to F for CTL or HFpEF, respectively. Predicted (abscissa) represents predicted SV using the respective goodness of fit equation (y = mx + b) from univariate regressions in panels A to F, whereas residuals (ordinate), represent the difference between observed SV (via either ECHO or acetylene) and predicted SV. In panel G, for corresponding regression plots where ECHO was set as the criterion see the ( Fig. 2, D to F, respectively), which led to differences between panels A versus D (P G 0.01) as well as C versus F (P = 0.04), but trending for D versus E (P = 0.07). Moreover, consistent with larger, but not significant increases in R 2 from rest to 20 W within HFpEF (P = 0.10, 0.52, and 0.88 for panels D, E, and F, respectively, between Fig. 1 and 2 ), which were accompanied by smaller SEE in HFpEF (Table 3) , the splay of data in residual versus predicted SV plots in panels G to I of Figure 2 appeared improved from rest to 20 W, while also remaining stronger compared with controls.
Lastly, persisting from 20 W, Figure 3 (A to C) illustrates SV ECHO could not explain the variance in SV ACET , nor could O 2pulse explain the variance in SV ECHO in controls, whereas linearity between O 2pulse and SV ACET increased modestly from 20 W (P = 0.68). Alternatively, while strength of R 2 presented in Figure 3 , panels D and F, carried over from 20 W to peak exercise within HFpEF, less of the variance in SV ECHO appeared to be explained by O 2pulse in Figure 3E versus Figure 2E (P = 0.28). Nevertheless, smaller standardized SEE across SV ECHO , SV ACET , and O 2pulse at both rest and 20 W in HFpEF versus controls was maintained at peak exercise, to which residual versus predicted SV plots in Figure 3 (G to I) appeared to remain consistent with the more favorable spread of data at 20 W in HFpEF compared to controls.
DISCUSSION
As an important clinical diagnostic tool, the prognostic power of CPET is strengthened when accompanied by objective measurements of exercise cardiac hemodynamics in patients with HFpEF (1, 5, 6, 17, 24, 29, 34) . Therefore, this study aimed to address a clinically impactful gap in knowledge by testing in a generalizable laboratory setting the (quasi)concurrent validity of noninvasive measures or estimates of exercise SV using a more recognized ECHO approach against lesser understood C 2 H 2 uptake and O 2pulse methods in patients with HFpEF.
These clinically translational data suggest that exercise SV can be measured or predicted with similar levels of precision using SV ECHO , SV ACET , or O 2pulse in patients with HFpEF. This study did not use invasive cardiac hemodynamic techniques to establish true construct validity of SV ECHO , SV ACET , or O 2pulse as noninvasive approaches to measure or estimate exercise SV in HFpEF. However, in various studies across the adult health spectrum (e.g., pulmonary hypertension, reduced ejection fraction HF, and so on), all three noninvasive approaches studied at present have been tested, while demonstrating validity with respect to ''gold'' standard methodology at rest and/or exercise conditions (2, 16, 19, 20, 32, 33, 37, 40) . Although we appreciate the physiologic-based constructs supporting the utility of the present techniques in patients with pulmonary and/or cardiac limitations, we recognize the direct translation from previous reports suggesting robust validity of SV ECHO , SV ACET , or O 2pulse cannot at this time be fully recognized in HFpEF. Therefore, in a translational and clinically impactful manner, and a necessary first step toward proper construct validation testing of the present methods in HFpEF, these data lend immediate support for the high-priority need to confirm the present observations in the setting of a more complex exercise catheterization study in patients with HFpEF.
While the direct Fick method involving catheterization is the ''gold'' standard for measuring cardiac hemodynamics, there are limitations associated with this approach that aid in providing firm reasoning for the aims tested in this study as well as in previous reports (2, 16, 19, 20, 32, 33, 37, 40) . For example, although highly trained specialists are tasked with performing catheterization procedures, patients are inherently exposed to increased risks associated with these techniques. This includes modest, but meaningful susceptibility to postoperative bleeding, cardiac events (e.g., myocardial infarction), ) . Controls, n = 18. HFpEF, n = 18. The SEE can be interpreted as given a predicted measurement of SV using a practical method relative to a set quasicriterion method (i.e., C 2 H 2 or ECHO), it can be assumed that the predicted SV is likely to vary within plus or minus the SEE value on the SV measured using the quasicriterion method with 68% confidence.
and in worst cases, patient death (3). Moreover, and of secondary importance beyond increased patient risk, because of complexities involved with cardiac catheterizations, resources that must be dedicated to performing these types of procedures are costly to patients as well as medical center (e.g., personnel, facilities, and so on), which contributes to the lack of routine availability of cardiac catheterization across institutions. Lastly, although it is recognized that interpretability of cardiac, pulmonary, and vascular responses during CPET is most robust and, hence, clinically preferred while performed in the upright position (e.g., treadmill or ergometry), it is not standard for centers that have the resources and willingness to perform cardiac catheterization during CPET that treadmill testing or upright ergometry are performed as opposed to supine ergometry. With this, although we are unaware of any study to date that specifically compares the clinical diagnostic strength of supine versus upright exercise concomitant with invasive cardiac hemodynamic testing in HFpEF, it should be considered when interpreting supine CPET that both hemodynamics and ventilation may be altered based on effects of body position (e.g., upward diaphragm shift, central to peripheral blood flow distribution, and so on) independent of pathologic state (22) , whereby the full extent of cardiovascular impairment may be falsely lessened. Echocardiography in HFpEF. In acknowledging ECHO for the noninvasive assessment of cardiac hemodynamics is likely the most used noninvasive technique in clinical and research settings, the presumptive link between prevalence of technique use and invariability in accuracy, precision, and reliability are not mutually exclusive to ECHO (9, 23, 25, 32) . Although a comprehensive review of the strengths and limitations of ECHO are beyond the scope of this report, in brief, it has been suggested that despite validation studies and established guidelines (9, 19, 23, 25, 28, 32) , variability associated For panels A to F, the variable set on the abscissa was considered the practical method, whereas the variable set on the ordinate was considered the quasi-criterion method. Panels G to I align vertically with panels A to C or D to F for CTL or HFpEF, respectively. Predicted (abscissa), represents predicted SV using the respective goodness of fit equation (y = mx + b) from univariate regressions in panels A to F, whereas residuals (ordinate), represent the difference between observed SV (via either ECHO or acetylene) and predicted SV. In panel G, for corresponding regression plots where ECHO was set as the criterion see the Figure http://www.acsm-msse.org with the process of image acquisition and postprocessing calculation of Q and SV is contributed by confounding degrees of human factors (e.g., sonographer experience), test setting (e.g., rest vs exercise, or supine vs upright exercise), patient factors (e.g., chest adiposity), acquisition protocols, and technology platforms (9, 23, 25, 28, 32) . Despite these proposed documented limitations, which may influence the utility of ECHO for exercise SV measurement in HFpEF, confounding sources of variability may be lessened when techniques are conducted by experienced sonographers in combination with skilled ECHO readers (9, 19, 23, 25, 28, 32) .
Acetylene uptake in HFpEF. In light of recent observations in HFpEF, in addition to previous work in reduced ejection fraction HF, we acknowledge that the potential impact changes in lung diffusing capacity and pulmonary capillary volume might have on measures of gas uptake within lungs cannot be overlooked (17, 30, 35) . For example, the presence of subclinical or overt pulmonary edema could theoretically influence the accuracy of SV ACET since the perfusion sensitive inert gas uptake technique assumes free diffusion of C 2 H 2 across the alveolar-capillary membrane. However, despite low lung diffusing capacity in HFpEF (17, 30) , similar to that observed in reduced ejection fraction HF (35) , these data suggest that the relative precision of SV measured using C 2 H 2 is linearly related to SV ECHO (the latter of which is not directly influenced by low lung diffusing capacity) while also appearing closely related to O 2pulse during CPET in HFpEF.
Although we support with tests of concurrent validity (i.e., R 2 , SEE, and so on (18)) encouraging data comparing SV ACET , SV ECHO , and O 2pulse during CPET in HFpEF, we recognize that cross-technique validity in the setting of our paradigm may have a higher likelihood of being influenced by changes For panels A to F, the variable set on the abscissa was considered the practical method, whereas the variable set on the ordinate was considered the quasi-criterion method. Panels G to I align vertically with panels A to C or D to F for CTL or HFpEF, respectively. Predicted (abscissa), represents predicted SV using the respective goodness of fit equation (y = mx + b) from univariate regressions in panels A to F, whereas residuals (ordinate), represent the difference between observed SV (via either ECHO or acetylene) and predicted SV. In panel G, for corresponding regression plots where ECHO was set as the criterion see the Figure in any physiologic construct underpinning the relevant method as well as the period of measurement (e.g., rest, 20 W, or peak exercise). For example, there appeared to be modest inconsistencies in the magnitude of explained variance between O 2pulse and SV ECHO versus comparisons of O 2pulse and SV ACET or SV ECHO and SV ACET when transitioning from rest through to peak exercise in HFpEF. Although only theoretical based on these data, it could be reasoned that because of intrinsic physiologic and anatomic adjustments of the pulmonary system that are provoked by exercise, which may include for example, increases in pulmonary capillary recruitment, collateral recruitment of airways, increased blood flow to lung apices, and alveoli unfolding; favorable changes in alveoli-pulmonary capillary interactions similarly affected SV ACET and O 2pulse without having any direct effect on SV ECHO . These global pulmonary interactions may have led to more consistency in the rise between SV ACET and O 2pulse observed in HFpEF. By contrast, because of major differences in gas properties between C 2 H 2 and O 2 , such as the lesser Bunsen solubility coefficient in blood demonstrated by O 2 (G30 times that of C 2 H 2 ) (8, 31) , it may be that lower lung diffusing capacity (30) accompanied by the potential for maldistribution of pulmonary capillary blood volume, is more influential to V O 2 and O 2pulse dynamics than what would be expected by C 2 H 2 at peak exercise in HFpEF. Although these hypotheses aimed to explain some of the modest variability with respect to interactions between O 2pulse and SV ECHO cannot be confirmed at present, we are encouraged by the consistency of SV ACET in relation to both O 2pulse and SV ECHO as a tool to measure SV during CPET in HFpEF. It follows, therefore, that with advanced construct validation testing, SV ACET may fulfill an immediate need-based gap for the routine clinical evaluation of exercise cardiac hemodynamics in HFpEF.
Comparison of inert gas uptake studies. In reaffirming our appreciation for previous studies describing various high blood soluble inert gas uptake techniques for measuring cardiac hemodynamics, we suggest that these data are consistent with Saur et al. (33) who demonstrated across patients with pulmonary disease that lung diffusing capacity does not significantly influence measures of Q via N 2 O uptake (physiologically relevant because of effects on perfusion sensitivity; compared with C 2 H 2 , N 2 O demonstrates an approximately twofold lower Bunsen solubility coefficient in blood ( [15] )). Likewise, the present observations in HFpEF support and extend the work of others who have reported that C 2 H 2 (16, 20, 36) , N 2 O (2,26), and/or CO 2 (13) techniques can be used to measure Q and SV in conditions of rest as well as exercise in various conditions of adult health or disease.
O 2pulse in HFpEF. With acknowledgement that there are studies demonstrating strong linearity between O 2pulse and SV during exercise in adults (4, 12, 37, 40) , it is also noteworthy that with marked variability in A-V O 2 and/or HR, it is unlikely O 2pulse can be used to predict SV. Although it is suggested that A-V O 2 and/or HR responses may be abnormal in individuals such as patients with HF who are strong candidates to demonstrate pathology of both central and peripheral organ systems (1, 21) , it is worth mentioning that Taylor et al. (37) (1) . Thus, the present observations offer support for the need to confirm via advanced exercise cardiac catheterization studies that there is utility in using O 2pulse to predict exercise SV in HFpEF.
Clinical implications. In the absence of reported adverse events directly associated with the ECHO technique as implemented in this study, it is also relevant that it has been demonstrated that inert gas uptake (i.e., C 2 H 2 ) at gas mix concentrations used in the study is safe in humans (38) . Therefore, with the intent of this study aimed at providing an advanced scientific and methodologic examination of noninvasive techniques for immediately measuring or estimating exercise SV in HFpEF, these data suggest that relative to one another, SV ACET , SV ECHO , and O 2pulse can be used with similar levels of precision during CPET to measure or predict SV in patients with HFpEF. In addition to being costeffective, noninvasive, and more widely available to patients and practitioners, these data with support from sound scientific reasoning, suggest it is feasible (via approaches tested presently) that noninvasive assessment of exercise cardiac hemodynamics may be routinely available to quickly grade syndrome severity and response to therapy in HFpEF.
The need to demonstrate generalizable laboratory-based efficacy across the present noninvasive techniques all tested within the same study of HFpEF is well supported as previous work from our group and others demonstrate there is indeed an important role for cardiac-centric contributors to exercise intolerance in HFpEF (1, 5, 6, 24, 29) . Again, although we appreciate hypotheses-generating suggestions that there are important contributions from pathology of the periphery to exercise intolerance in HFpEF (21), we cannot emphasize to a greater extent that these data have an immediate high-priority translational impact with respect to strengthening the clinical decision making process linked to CPET in HFpEF. Likewise, additional availability to cardiac hemodynamic responses to CPET will serve to improve our understanding of the role that impaired cardiac hemodynamics play in the pathophysiology exercise intolerance in HFpEF.
Limitations. In addition to previously discussed technique specific limitations, we recognize that in all cases that exerciserelated interstitial pulmonary edema and V A /Q mismatch may occur in HFpEF patients. Although abnormal shifts in perfusion, such as extrapulmonary R-to-L shunt, may be detectable via ECHO (e.g., obvious cases of septal defects), the presence of pulmonary edema and/or inhomogeneous ventilation has the potential to not only affect ventilation-based techniques, but also the mirrored projection and reflection of PW beams associated with PW-TDI ECHO and, subsequently, the quality of image acquisition associated with ECHO (14, 19, 23, 25, 32) . Nevertheless, although cardiac catheterization studies were not performed at present, we are confident that we identified and recruited patients for this study who did not demonstrate overt signs or symptoms to suggest the presence of these or other cardiac and pulmonary limitations, which could lead to marked technique influencing V A /Q mismatch (see Figure, Supplemental Digital Content 2, which demonstrates surrogate estimates of whole lung V A /Q matching cannot explain variance associated with SV ACET , SV ECHO , and O 2pulse at any timepoint in HFpEF, http://links.lww.com/MSS/A936).
Moreover, it could be interpreted from studies of lung diffusing capacity, while being supported by validation studies of Q via inert gas uptake (2, 13, 16, 26, 33) , that in the absence of severe impediment (e.g., presence of marked exercise provocation of accumulated interstitial pulmonary edema, parenchymal disease, and so on) of the free diffusion of high blood soluble inert gas across the alveolar-capillary membrane barrier, it is not likely that low lung diffusing capacity would be influential to the perfusion sensitive inert gas uptake technique for the measurement of exercise SV in HFpEF (8, 16, 26, 33) . Additionally, as previously discussed, a ''gold'' standard criterion technique (e.g., direct Fick) that was in addition to our three noninvasive techniques was not included in this study and, therefore, construct validity across SV ECHO , SV ACET , and O 2pulse in this experimental paradigm cannot be confirmed with these data. Although the exact translation to this study based on previous patient centered studies of noninvasive approaches to assess cardiac hemodynamics is not clear, we note that individual studies of each of the techniques employed in this study have been tested for validity against true criterion techniques, while accompanied by favorable observations (2, 13, 16, 19, 26, 33, 37) .
Lastly, relevant to the discussion of O 2pulse , it must be acknowledged that effects of rate-limiting therapy (i.e., Ablockers) on a blunted rise in HR may in part account for some unexplained variance associated with O 2pulse during CPET in HFpEF. Although we would not expect to observe marked increases in SV ECHO or SV ACET via an improved Frank-Starling effect given the afterload dependence of HF, a A-blocker effect may have plausibly led to an overestimation of SV by O 2pulse as opposed to our interpretations suggesting underestimation. While a deeper understanding of whether the influence of pharmacologic therapy markedly confounded the present observations is of certain intrigue at a mechanistic level, it is of greater applicability to the larger clinical implications of these data that real-world HFpEF patients typically perform CPET in an optimally medicated state, which suggests these data may be more generalizable to a classical clinical setting.
CONCLUSIONS
By implementing physiologic-based scientifically rigorous and sound methodologic testing of SV ACET , SV ECHO , and O 2pulse for the measurement or prediction of SV during CPET in patients with HFpEF, these data suggest that each noninvasive technique can be used at similar levels of precision in a test setting that is generalizable and immediately clinically relevant to patients with HFpEF. Therefore, because CPET accompanied by objective assessment of cardiac hemodynamics has immediate clinical translational implications for its key role in assisting in the clinical classification of HFpEF (1, 5, 6, 17, 24, 29) , the scientific aims tested in this study constitute a primary original step in lending physiologic-based support for the need to perform construct validation studies of each of the present methods while involving ''gold'' standard techniques during CPET in HFpEF.
